Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center.
Acromegaly
/ complications
Adult
Aged
Blood Glucose
/ metabolism
Blood Pressure
Electrocardiography
Female
Glucose Tolerance Test
Hospitalization
Human Growth Hormone
/ metabolism
Humans
Insulin-Like Growth Factor I
/ biosynthesis
Lipids
/ blood
Male
Middle Aged
Pituitary Neoplasms
/ complications
Poland
/ epidemiology
Retrospective Studies
Young Adult
GH
IGF-I
acromegaly
comorbidity
complication
pituitary adenoma
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
12
2020
accepted:
16
02
2021
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
15
1
2022
Statut:
epublish
Résumé
In acromegaly, chronic exposure to impaired GH and IGF-I levels leads to the development of typical acromegaly symptoms, and multiple systemic complications as cardiovascular, metabolic, respiratory, endocrine, and bone disorders. Acromegaly comorbidities contribute to decreased life quality and premature mortality. The aim of our study was to assess the frequency of acromegaly complications and to evaluate diagnostic methods performed toward recognition of them. It was a retrospective study and we analyzed data of 179 patients hospitalized in the Department of Endocrinology, Diabetes and Isotope Therapy in Wroclaw Medical University (Poland) in 1976 to 2018 to create a database for statistical analysis. The study group comprised of 119 women (66%) and 60 men (34%). The median age of acromegaly diagnosis was 50.5 years old for women (age range 20-78) and 46 for men (range 24-76). Metabolic disorders (hyperlipidemia, diabetes, and prediabetes) were the most frequently diagnosed complications in our study, followed by cardiovascular diseases and endocrine disorders (goiter, pituitary insufficiency, osteoporosis). BP measurement, ECG, lipid profile, fasting glucose or OGTT were performed the most often, while colonoscopy and echocardiogram were the least frequent. In our population we observed female predominance. We revealed a decrease in the number of patients with active acromegaly and an increase in the number of well-controlled patients. More than 50% of patients demonstrated a coexistence of cardiac, metabolic and endocrine disturbances and only 5% of patients did not suffer from any disease from those main groups.
Identifiants
pubmed: 33796075
doi: 10.3389/fendo.2021.642131
pmc: PMC8009182
doi:
Substances chimiques
Blood Glucose
0
IGF1 protein, human
0
Lipids
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
642131Informations de copyright
Copyright © 2021 Rolla, Jawiarczyk-Przybyłowska, Halupczok-Żyła, Kałużny, Konopka, Błoniecka, Zieliński and Bolanowski.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):64-67
pubmed: 28740584
J Endocrinol Invest. 2003 Dec;26(12):1242-7
pubmed: 15055479
Pituitary. 2017 Feb;20(1):70-75
pubmed: 27631334
Eur J Endocrinol. 2017 May;176(5):645-655
pubmed: 28246150
Endocrine. 2015 Feb;48(1):25-35
pubmed: 24972804
Endocr Rev. 2010 Jun;31(3):301-42
pubmed: 20086217
Pituitary. 2014 Aug;17(4):333-41
pubmed: 24037646
Endokrynol Pol. 2019;70(1):2-18
pubmed: 30843181
Horm Metab Res. 2017 Jun;49(6):440-445
pubmed: 28472827
Front Endocrinol (Lausanne). 2017 Mar 03;8:40
pubmed: 28316591
Arch Med Sci. 2018 Aug;14(5):951-961
pubmed: 30154875
Clin Cases Miner Bone Metab. 2011 Sep;8(3):37-43
pubmed: 22461828
Front Endocrinol (Lausanne). 2019 Sep 24;10:643
pubmed: 31616375
Eur J Endocrinol. 2012 Dec 10;168(1):39-47
pubmed: 23087126
Endocr Relat Cancer. 2017 Oct;24(10):505-518
pubmed: 28733467
Endocr Rev. 2018 Aug 1;39(4):440-488
pubmed: 29684108
Osteoporos Int. 2016 Mar;27(3):1123-1129
pubmed: 26446771
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
Pituitary. 2017 Feb;20(1):46-62
pubmed: 28224405
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
Arch Endocrinol Metab. 2020 May-Jun;64(3):269-275
pubmed: 32555993
Endocr Relat Cancer. 2015 Jun;23(6):469-80
pubmed: 27185871
BMC Endocr Disord. 2014 Dec 16;14:97
pubmed: 25511633
Arch Endocrinol Metab. 2019 Nov-Dec;63(6):630-637
pubmed: 31939488
Front Public Health. 2020 Apr 28;8:147
pubmed: 32411649
Endocr Rev. 2004 Feb;25(1):102-52
pubmed: 14769829
PLoS One. 2014 Feb 14;9(2):e88787
pubmed: 24551163
Endocrine. 2017 Feb;55(2):346-359
pubmed: 28042644
Endokrynol Pol. 2020;71(4):285-291
pubmed: 32901908
Eur J Endocrinol. 2012 Aug;167(2):189-98
pubmed: 22596288
Pituitary. 2013 Sep;16(3):294-302
pubmed: 22903574
Endocr Rev. 2019 Feb 1;40(1):268-332
pubmed: 30184064
Endocr Rev. 2009 Apr;30(2):152-77
pubmed: 19240267
J Clin Endocrinol Metab. 2013 Aug;98(8):3402-10
pubmed: 23771918
Curr Diab Rep. 2017 Feb;17(2):8
pubmed: 28150161
J Formos Med Assoc. 2019 Nov;118(11):1488-1493
pubmed: 31147197
J Neurosurg. 2015 Apr;122(4):798-802
pubmed: 25423276
Eur J Endocrinol. 2007 Oct;157(4):399-409
pubmed: 17893253
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31606735
Pituitary. 2016 Aug;19(4):448-57
pubmed: 27279011
Sichuan Da Xue Xue Bao Yi Xue Ban. 2019 May;50(3):433-437
pubmed: 31631614
Front Horm Res. 2018;49:20-28
pubmed: 29895013
Endocrine. 2018 Nov;62(2):448-455
pubmed: 30051198
Endocrinol Nutr. 2013 Oct;60(8):470-4
pubmed: 23246411
Neurosurg Focus. 2020 Jun;48(6):E10
pubmed: 32480366
Exp Clin Endocrinol Diabetes. 2020 Feb;128(2):104-110
pubmed: 30332686
J Endocrinol Invest. 2002 Mar;25(3):240-5
pubmed: 11936466
Front Endocrinol (Lausanne). 2020 Jan 14;10:899
pubmed: 32010060